SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A SUBCUTANEOUS DOSING REGIMEN (FUTURE 2)

被引：1

作者：

McInnes, I. B. ^{[1
]}

Mease, P. ^{[2
,3
]}

Kirkham, B. ^{[4
]}

Kavanaugh, A. ^{[5
]}

Ritchlin, C. ^{[6
]}

Rahman, P. ^{[7
]}

Van der Heijde, D. ^{[8
]}

Landewe, R. ^{[9
,10
]}

Conaghan, P. G. ^{[11
]}

Gottlieb, A. B. ^{[12
]}

Richards, H. ^{[13
]}

Ligozio, G. ^{[14
]}

Pricop, L. ^{[14
]}

Mpofu, S. ^{[13
]}

机构：

[1] Univ Glasgow, Glasgow, Lanark, Scotland

[2] Swedish Med Ctr, Seattle, WA USA

[3] Univ Washington, Seattle, WA 98195 USA

[4] Guys & St Thomas Hosp, London, England

[5] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

[6] Univ Rochester, Med Ctr, New York, NY USA

[7] Mem Univ, St John, NF, Canada

[8] Leiden Univ, Med Ctr, Leiden, Netherlands

[9] Univ Amsterdam, Amsterdam, Netherlands

[10] Atrium Med Ctr, Amsterdam, Netherlands

[11] Univ Leeds, Leeds, W Yorkshire, England

[12] Tufts Med Ctr, Boston, MA USA

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Pharmaceut, E Hanover, NJ USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2015-eular.2265

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0425

引用

页码：352 / 353

页数：3